Tag Archives: mandate

Hot Investor Mandate 1: Korean VC Firm with Pharma Affiliation Seeks to Invest in Early Stage Therapeutics Assets, Most Interested in Oncology and Autoimmune Disease

5 Jul

A Seoul-based venture capital firm founded in 2015 and affiliated with a leading pharmaceutical company in South Korea closed their first fund in 2016 and has recently raised a second fund of approximately $60M USD. The firm has made 8 investments to date, in 3 Korean and 5 USA-based companies. The firm continues to seek global opportunities. The firm generally participates in financings of Series B and beyond, participating in Series A rounds on a case-by-case basis. However, the firm has started to look for earlier stage opportunities and is most interested in spin-out assets and forming new companies in South Korea. Within this angle, the firm is highly interested in companies who are interested in entering the Korean market and looking to leverage on the capital and clinical infrastructure in South Korea.

The firm is focused on therapeutics companies and does not invest in medical devices, diagnostics, or digital health. The firm is open to considering assets of very early stages, even those as early as lead optimization phase. The firm considers various modalities, including antibodies, small molecules, and cell therapy. Currently, the firm is not interested in gene therapy. Indication-wise, the firm is most interested in oncology and autoimmune diseases but has recently looked at fibrotic diseases and certain rare diseases as well.

With regards to companies raising a Series A round, the firm prefers working with experienced management teams with high-profile scientific founders being involved. The firm incorporates a different strategy depending on the company’s headquarters. For companies based in South Korea, the firm serves as a hands-on, active investor and seeks board representation. In the USA, the firm prefers to be a more passive investor and generally seeks to co-invest with established venture capital firms that have a footprint in the USA.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 2: Hong Kong Boutique VC Firm Invests in All Kinds of Healthcare Technologies and Most Interested in Large Disease Markets of Unmet Medical Need

5 Jul

A boutique venture capital firm founded in Hong Kong currently manages a $100M USD fund and a $200M RMB fund. The fund is industry agnostic within China while it focuses only on healthcare ex-China. The firm generally participates in Series A or B rounds but would also consider seed and growth-stage funding. Typical equity investment size ranges from $1-5M. The firm is open to both leading and co-investing. The firm is actively seeking new opportunities from across the world with a focus on companies in China, U.S., Europe, and Israel. The firm helps portfolio companies get into massive and fast-growing markets of China and Asia, and assists Chinese companies to expand abroad.

The firm is opportunistic across all subsectors of healthcare. Within MedTech, the firm is most interested in medical devices, artificial intelligence, robotics, and mobile health. The firm is seeking post-prototype innovations that are FDA cleared or are close to receiving clearance. Within therapeutics, the firm is interested in therapeutics for large disease markets such as oncology, neurology, and metabolic diseases. The firm is open to all modalities with a special interest in immunotherapy and cell therapy.

The firm is in search of ambitious companies with strong, experienced management teams. The firm takes a hands-on approach to portfolio companies and can work with incomplete teams. The firm can contribute expertise in essential services: branding, marketing, channel development, overseas expansion, human resources and finance. The firm may also request distribution or negotiation rights in China.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 3: Strategic Investment Firm of Large Pharma Invests in Early and Late Stage Therapeutics & Drug-Device Combinations, Especially Interested in Orphan and Rare Diseases

5 Jul

A strategic investment firm of a large global pharmaceutical makes investments ranging from $5 million to $30 million, acting either as a sole investor or within a syndicate. The firm is open to considering therapeutic opportunities globally, but only if the company is pursuing a market opportunity in the USA and is in dialogue with the US FDA.

The firm invests in therapeutics, and in this sector the firm is interested in both early and late stage assets. The firm will consider any type of therapeutic technology (including small molecules, large molecules and gene therapies), and has a strong preference for investing in orphan drugs and other niche disease areas. It is preferred that indications have validated clinical endpoints and can be studied using small trials. Indications that require large clinical trials, including as cardiovascular diseases, CNS diseases and primary care indications (such as influenza) will not be considered. Drug-device combinations will also be considered.

The firm prefers to work with companies who have opened dialogue with the FDA. The firm considers a high-quality management team to be a significant requirement of their investment criteria. It is preferred that assets can reach the marketplace 3-5 years post-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 4: USA-Based Investment Firm Can Invest Over $10M in Innovative Medtech and Digital Health Companies Based in Texas or Southwestern USA

5 Jul

A venture capital firm that was founded in 2006 and is based in the Southern USA has managed $400 million in total assets, and recently closed its sixth fund. The firm typically makes equity investments into enterprise software, medical devices, and healthcare IT companies in the seed, series A, series B and series C stages. The typical investment size ranges from $3 million to $10+ million per company. The allocation numbers will vary over the next 6-9 months. For early-stage investments, the firm primarily invests in companies based in Texas, but they will also consider opportunities in the Southwest of the US.

The firm is currently looking for new investment opportunities in enterprise software, medical devices, and the healthcare IT space. The firm will invest in 510k devices and healthcare IT companies, and it is very opportunistic in terms of indications. In the past, the firm was active in medical device companies developing dental devices, endovascular innovation devices, and women’s health devices.

The firm generally seeks to invest in private companies. The firm will consider pre-revenue companies and has no specific requirements for the company’s management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 1: Global VC Firm Headquartered in Asia Invests in All Parts of Therapeutics, Medical Devices, Diagnostics, and Digital Health

28 Jun

A venture capital firm founded in 2005 has multiple offices throughout Asia, New York, and San Diego. The firm has closed its fifth fund in 2017 and is currently raising a sixth fund, which the firm is targeting to be the largest fund to date. The firm continues to actively seek investment opportunities across a wide range of industries. 1/3 of the fund is dedicated to global/USA-based life sciences and healthcare investments, while the rest of the fund will focus on investing in Asia-based companies. On average, the initial size of investment is in the $2-5M range but the firm has the capacity to invest more in companies they identify as a strong fit. The firm can participate anywhere from Seed to Series B, but Series A is their sweet spot.

The firm is an opportunistic investor and will consider therapeutics, medical devices, diagnostics, and healthcare IT companies. However, the firm will generally avoid single therapeutic assets and those that are pre-clinical or earlier. The firm is open to novel medical devices of all FDA regulatory pathways, including 510k and PMA. The firm is strongly interested in platform plays, or technologies that have implications in multiple disease areas or indications. Examples include novel drug delivery platforms, drug discovery platforms that leverage AI or machine learning, regenerative medicine, etc.

The firm considers the management team’s character and entrepreneurial spirit – more so than the team’s experience – as one of the most important factors in the investment screening process. Each partner of the firm will dedicate their time to become acquainted with the management team and determine their degree of fit. The targeted market and the company’s competitive edge are also important considerations. The firm prefers to act as the lead investor and will seek board representation, but is also open to co-investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 2: USA-Based Venture Capital Firm Invests in Medical Devices, Diagnostics, and Digital Health with Strong Interests in Applications of AI and Machine Learning

28 Jun

A venture capital company founded in 2005 and located in California manages just under $70 million in assets across 2 funds and makes equity investments into companies ranging from a few hundred thousand dollars to $2 million with additional capital reserved for follow on rounds. The firm is looking for companies located throughout the United States and plans to make 4 new investments over the next 6-9 months.

The firm is looking for companies developing Medical Devices and Diagnostics, Healthcare IT products and Life Science Research Tools with an emphasis on fast to market low capital intense products that reduce the cost of delivering quality healthcare. For Healthcare IT investments the firm is most interested in machine learning and artificial intelligence (AI) applications and is generally not interested in Telehealth and EMR solutions. The firm is open to all sub-sectors and indications in the Medical technology space except for those targeting diseases and disorders of the spine. The firm will invest in both seed and later stage companies.

The firm is looking for companies with skilled and experienced management teams. The firm generally looks to take a board seat into companies after investment and play and active role in the management. The firm is willing to invest in both public and privately held companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 3: VC Firm Seeks Investment Opportunities in Digital Health and Medical Device Technologies that Address Problems of Large Unmet Need in Healthcare

28 Jun

A venture capital firm spun out of a leading university looks to provide primarily seed stage financings to companies ranging from $100K – $500k initially with up to $5-6 million provided over the lifetime of the investment. The firm prefers to invest in companies in the Eastern United States but is open to considering companies from around the globe. The firm could make as many as 6-7 investments over the next 6-9 months.

The firm is looking for companies working in sectors of digital health and more selectively medical devices. The firm is only interested in companies that are targeting very larger markets/unmet needs and is not interested in companies that require FDA Approval. The firm is especially interested in companies utilizing software for the optimization of various products and processes within healthcare. The firm is not interested in consumer-facing products.

The firm is very open to working with young entrepreneurs and generally looks to take a board seat following the investment. The firm is looking for companies with the potential to become very large organizations capable of being worth hundreds of millions of dollars.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

%d bloggers like this: